Genome-wide association studies: how predictable is a person’s cancer risk?

References

• Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature406, 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med.347, 1999–2009 (2002).
   PubMed Web of Science ®Google Scholar
• Huang CC, Bredel M. Use of gene signatures to improve risk estimation in cancer. JAMA299(13), 1605–1606 (2008).
   PubMedGoogle Scholar
• Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J. Clin. Oncol.27(8), 1337–1338 (2009).
   PubMedGoogle Scholar
• Donnelly P. Progress and challenges in genome-wide association studies in humans. Nature456, 728–731 (2008).
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Khoury MJ, Drazen JM. Letting the genome out of the bottle – will we get our wish? N. Engl. J. Med.358(2), 105–107 (2008).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann. Surg. Oncol.16, 772–773 (2009).
   PubMedGoogle Scholar
• Kaiser J. Breakthrough of the year. It’s all about me. Science318(5858), 1843 (2007).
   PubMedGoogle Scholar
• Nowell PC. The clonal evolution of tumor cell populations. Science194(4260), 23–28 (1976).
   PubMed Web of Science ®Google Scholar
• Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther.6(3), 308–312 (2007).
   PubMed Web of Science ®Google Scholar
• International HapMap Consortium, Frazer KA, Ballinger DG, Cox DR et al. A second-generation human haplotype map of over 3.1 million SNPs. Nature449(7164), 851–861 (2007).
   PubMed Web of Science ®Google Scholar
• Rockman MV. Reverse engineering the genotype–phenotype map with natural genetic variation. Nature456, 738–744 (2008).
   PubMed Web of Science ®Google Scholar
• Stern DL, Orgogozo V. The loci of evolution: how predictable is genetic evolution? Evolution62(9), 2155–2177 (2008).
   PubMedGoogle Scholar
• Easton DF, Eeles RA. Genome-wide association studies in cancer. Hum. Mol. Genet.15(17 R2), R109–R115 (2008).
   Google Scholar
• Roukos DH. Assessing both genetic variation (SNPs/CNVs) and gene–environment interactions may lead to personalized gastric cancer prevention. Expert Rev. Mol. Diagn.9(1), 1–6 (2009).
   PubMed Web of Science ®Google Scholar
• Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet.39, 865–869 (2007).
   PubMed Web of Science ®Google Scholar
• Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies breast cancer susceptibility loci. Nature447, 1087–1093 (2007).
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Kraft P, Jacobs KB et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet.39, 870–874 (2007).
   PubMed Web of Science ®Google Scholar
• Eeles RA, Kote-Jarai J, Giles GG et al. Identification of multiple novel prostate cancer susceptibility loci by a genome-wide association study. Nat. Genet.40, 316–321 (2008).
   PubMedGoogle Scholar
• Thomas G, Jacobs KB, Yeager M et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet.40, 310–315 (2008).
   PubMed Web of Science ®Google Scholar
• Gudmundsson J, Sulem P, Manolescu A et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet.39, 631–637 (2007).
   PubMed Web of Science ®Google Scholar
• Gudmundsson J, Sulem P, Steinthorsdottir V et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat. Genet.39, 977–983 (2007).
   PubMed Web of Science ®Google Scholar
• Tenesa A, Farrington SM, Prendergast JG et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat. Genet.40, 631–637 (2008).
   PubMed Web of Science ®Google Scholar
• Amos CI, Wu X, Broderick P et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet.40, 616–622 (2008).
   PubMed Web of Science ®Google Scholar
• Study Group of Millennium Genome Project for Cancer; Sakamoto H, Yoshimura K, Saeki N et al. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat. Genet.40(6), 730–740 (2008).
   PubMed Web of Science ®Google Scholar
• Lee C, Morton CC. Structural genomic variation and personalized medicine. N. Engl. J. Med.358(7), 740–741 (2008).
   PubMedGoogle Scholar
• Roukos DH, Ziogas D. Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann. Surg. Oncol.16, 774–775 (2009).
   PubMedGoogle Scholar
• Hayden EC. Genome sequencing: the third generation. Nature457, 768–769 (2009).
   PubMedGoogle Scholar
• Roukos DH. Linking contralateral breast cancer with genetics. Radiother. Oncol.86, 139–141 (2008).
   PubMedGoogle Scholar
• Ziogas D, Baltogiannis G, Fatouros M, Roukos DH. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann. Surg.247(4), 714–715 (2008).
   PubMedGoogle Scholar
• Roukos DH. Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev. Mol. Diagn.8(5), 587–597 (2008).
   PubMed Web of Science ®Google Scholar
• Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med.358, 197 (2008).
   PubMedGoogle Scholar
• Roukos DH. Breast-cancer stromal cells with TP53 mutations. N. Engl. J. Med.358, 1636 (2008).
   PubMedGoogle Scholar
• Zhu J, Zhang B, Smith EN, Drees B et al. Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks. Nat. Genet.40(7), 854–861 (2008).
   PubMed Web of Science ®Google Scholar
• Smith EN, Kruglyak L. Gene–environment interaction in yeast gene expression. PLoS Biol.6(4), e83 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer9(1), 28–39 (2009).
   PubMed Web of Science ®Google Scholar
• Lewis J. From signals to patterns: space, time, and mathematics in developmental biology. Science322(5900), 399–403 (2008).
   PubMed Web of Science ®Google Scholar
• Bennett CN, Green JE. Unlocking the power of cross-species genomic analyses: identification of evolutionarily conserved breast cancer networks and validation of preclinical models. Breast Cancer Res.10(5), 213 (2008).
   PubMedGoogle Scholar
• Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene27(41), 5497–5510 (2008).
   PubMed Web of Science ®Google Scholar
• Deisboeck TS, Zhang L, Yoon J, Costa J. In silico cancer modeling: is it ready for prime time. Nat. Clin. Pract. Oncol.6(1), 34–42 (2009).
   PubMedGoogle Scholar